Please try another search
Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Name | Age | Since | Title |
---|---|---|---|
Cassian Yee | - | - | Member of Scientific Advisory Board |
Patrick Hwu | - | - | Member of Scientific Advisory Board |
Jeffrey S. Weber | - | - | Member of Scientific Advisory Board |
Mario Sznol | 65 | - | Member of Scientific Advisory Board |
Daniel J. Powell | - | - | Member of Scientific Advisory Board |
Iain D. Dukes | 65 | 2016 | Independent Chairman of the Board |
Wayne P. Rothbaum | 55 | 2016 | Independent Director |
Athena Maria Countouriotis | 51 | 2019 | Independent Director |
James J. Mule | - | - | Member of Scientific Advisory Board |
Wendy L. Yarno | 68 | 2023 | Independent Director |
Merrill A. McPeak | 87 | 2011 | Independent Director |
Ryan D. Maynard | 54 | 2015 | Independent Director |
Michael Weiser | 60 | 2018 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review